Key Highlights

  • Oruka Therapeutics (NASDAQ:ORKA) rose 8.37% to about USD 86.86 in early trading on Monday, October 26, 2026, after Phase 2b data showed a PASI 100 rate of 61% at 600 mg against 0% for placebo among 187 patients.
  • Aptevo Therapeutics (NASDAQ:APVO) rose 6.83% to USD 1.72 after reporting that 10 of 47 evaluable frontline acute myeloid leukaemia patients (21%) on mipletamig combination therapy advanced to stem cell transplant.
  • Cumberland Pharmaceuticals (NASDAQ:CPIX) fell 14.49% to USD 7.26 after a Phase 2a trial of 41 subjects drew no efficacy conclusions, while NeOnc Technologies (NASDAQ:NTHI) rose 10.7% to about USD 3.62 on a planned trial.
  • The common theme is that sample size, comparator and trial stage decided the reaction: a controlled Phase 2b and a transplant comparison lifted shares, while an underpowered study and a plan with a going concern risk drew different responses.

Oruka Therapeutics (NASDAQ:ORKA): a controlled Phase 2b with dose response

Oruka Therapeutics (NASDAQ:ORKA), a clinical-stage biotechnology company, released Week 16 results for ORKA-001 at 7:00 a.m. ET on Monday, October 26, 2026, and the shares rose 8.37% to about USD 86.86 in early trading, with prices described as intraday. EVERLAST-B is a Phase 2b trial that randomised 187 patients 1:1:1:1. The primary endpoint, PASI 100, means complete clearance of psoriasis skin lesions. It was reached by 61% of patients on 600 mg, 44% on 300 mg and 43% on 37.5 mg, against 0% on placebo, and the high-dose result was statistically significant at p<0.0001.

The climb from 43% to 61% complete clearance shows that more drug produced more skin clearance, and adverse events occurred in 39% of the high-dose group against 43% on placebo. The risks are funding, since the release states no cash or runway, and durability, because patients who reached PASI 100 are re-randomised at Week 28 and the trial continues to Week 100. The company plans Phase 3 trials in the first half of 2027 and 52-week EVERLAST-A data in December 2026.

Secondary measures were closer together: PASI 90, a 90% improvement in skin disease, was 70%, 85% and 86% across the three doses. The most common events, upper respiratory infection and headache, occurred at rates similar to approved IL-23 inhibitors, and an 8.37% rise from a high price leaves little room for a slower Phase 3 start.

Aptevo Therapeutics (NASDAQ:APVO): a transplant rate against an external comparator

Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biotechnology company, saw its shares rise 6.83% to USD 1.72 in early trading on Monday, October 26, 2026, a price that is intraday. The company's release of that day reported that 10 of 47 evaluable frontline patients (21%) given mipletamig with venetoclax and azacitidine went on to allogeneic stem cell transplant. Nine came from the ongoing Phase 1b RAINIER trial and one from a completed dose expansion trial. The company cites the Phase 3 VIALE-A trial, where 3 of 286 patients (0.7%) given venetoclax and azacitidine alone later had a transplant.

A transplant, which uses donor cells, is the main route to a potentially curative outcome in acute myeloid leukaemia, so a therapy that moves more patients there addresses a central limit of frontline regimens. The comparison is across different trials and patient groups, so it is indicative only, as the company itself notes. The figure comes from a small, partly non-randomised dataset, the release gave no cash runway, and micro cap biotechnology shares often rely on equity financing that can dilute holders. RAINIER dosing evaluation is expected to finish by year-end 2026.

Cumberland Pharmaceuticals (NASDAQ:CPIX): an underpowered trial removes a catalyst

Cumberland Pharmaceuticals (NASDAQ:CPIX), a specialty pharmaceutical company, released top-line results from its Phase 2a ASSIST-SSc trial at 4:05 p.m. ET on Friday, October 23, 2026, after the close, so the first full reaction came in early trading on Monday, October 26, 2026. The shares traded at USD 7.26, down 14.49% from an implied Friday close near USD 8.49. The trial of ifetroban enrolled 41 subjects with systemic sclerosis, 31 on ifetroban and 10 on placebo, and the company stated that the study was not designed or powered to assess efficacy.

Most subjects in both arms showed limited disease progression, which left little room for a difference, and the company drew no efficacy conclusions. A safety-only readout removes a possible source of value, and the profile showed more gastrointestinal events and a modest rise in bleeding-related events with ifetroban. A call on the Duchenne muscular dystrophy programme was scheduled for Monday, October 26, 2026, a separate indication whose content may offset or add to Friday's results.

NeOnc Technologies (NASDAQ:NTHI): a planned trial with funding risk

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage company developing treatments for brain cancer, rose 10.7% to about USD 3.62 in early trading on Monday, October 26, 2026, after a company release at 9:19 a.m. ET. The release outlines a planned trial of about 500 patients at about 30 hospitals in three countries for NEO100, an investigational therapy delivered through the nose, and states that these are planned figures, not completed enrolment. It does not specify the trial phase, financing or cash position.

The release cites preliminary remission in 6 of 25 patients from a small, nonrandomised group that, in the company's own words, does not establish effectiveness. It lists the ability to continue as a going concern among its risk factors, and a trial of this scale would require substantial capital, often raised through share offerings. Short interest was reported to have risen about 45% to 758,000 shares, which can magnify swings.

The planned figures may change, the regulatory path is unstated and early remission data are not proof of efficacy. Investors should watch for a financing announcement and regulatory clearance for the trial, since a plan of this size depends on capital that the release does not describe.

Where Things Stand

The answer is that trial design decided how far each result could be trusted. Oruka (NASDAQ:ORKA) reported a randomised, placebo-controlled Phase 2b with a dose response, and Aptevo Therapeutics (NASDAQ:APVO) offered a 21% transplant rate against a 0.7% external comparison, both with funding questions. Cumberland Pharmaceuticals (NASDAQ:CPIX) delivered a safety-only study that drew no efficacy conclusions and fell 14.49%, while NeOnc Technologies (NASDAQ:NTHI) rose 10.7% on a plan rather than data while listing going concern risk. The next catalysts are the Fed decision on Wednesday, October 28, 2026, Oruka EVERLAST-A results in December 2026 and Aptevo RAINIER dosing by year-end 2026. Early trial results are not guarantees of later success, and this is not investment advice.